Literature DB >> 16099182

Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives.

Serguei Castaneda1, Michael S Boosalis, David Emery, Allison Thies, Douglas V Faller, Susan P Perrine.   

Abstract

Accelerated apoptosis of erythroid progenitors is a characteristic of beta-thalassemia which presents a significant barrier to definitive therapeutic approaches utilizing induction of endogenous fetal globin gene expression. gamma-globin gene expression may not be inducible in, or may not be able to rescue, erythroid cells in which programmed cell death is initiated early in erythroblast development. In this report, short-chain fatty acid derivatives (SCFADs) which induce fetal globin gene expression were tested for their ability to promote proliferation and survival of erythroid progenitors cultured from beta-thalassemic subjects, and of cytokine-dependent erythroid cell lines. Certain SCFADs promoted thalassemic Bfu-e growth and cytokine-independent growth and survival of erythroid cell lines. A 40-80% increase in erythroid Bfu-e colony number was observed in cultures established with any of five mitogenic SCFADs, compared to control or butyrate-treated cultures from the same subjects. Immunoblot analysis demonstrated that these same SCFADs also regulated the expression of specific protein inhibitors of apoptosis. Anti-apoptotic ratios of the proteins Bcl-xL/Bcl-xS in thalassemic Bfu-e were increased by 30-120% with exposure to the SCFDs, compared to the ratios in the same cells cultured under control conditions. Similar anti-apoptotic increases in Mcl-1L/Mcl-1S ratios were induced by the SCFADs. These findings suggest that select fetal globin-inducing SCFADs which enhance proliferation of beta-thalassemia progenitors may enhance survival of these progenitors by altering levels of Bcl-family protein members. This combination of effects should enhance erythroid cell survival in the beta-thalassemia syndromes, allowing fetal globin gene expression to be induced more effectively than currently available, growth-suppressing, fetal globin-inducing agents, such as the butyrates or chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099182      PMCID: PMC4260805          DOI: 10.1016/j.bcmd.2005.06.007

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  38 in total

Review 1.  Pharmacologic modulation of fetal hemoglobin.

Authors:  M H Steinberg; G P Rodgers
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

Review 2.  Advances in experimental treatment of beta-thalassaemia.

Authors:  G P Rodgers; Y Saunthararajah
Journal:  Expert Opin Investig Drugs       Date:  2001-05       Impact factor: 6.206

Review 3.  BCL-2 family: regulators of cell death.

Authors:  D T Chao; S J Korsmeyer
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Inhibition of estrogen-dependent breast cell responses with phenylacetate.

Authors:  S Sawatsri; D Samid; S Malkapuram; N Sidell
Journal:  Int J Cancer       Date:  2001-09-01       Impact factor: 7.396

5.  The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major.

Authors:  F Centis; L Tabellini; G Lucarelli; O Buffi; P Tonucci; B Persini; M Annibali; R Emiliani; A Iliescu; S Rapa; R Rossi; L Ma; E Angelucci; S L Schrier
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

6.  Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.

Authors:  James S Chen; Douglas V Faller
Journal:  J Cell Physiol       Date:  2005-01       Impact factor: 6.384

7.  Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia)

Authors:  J Yuan; E Angelucci; G Lucarelli; M Aljurf; L M Snyder; C R Kiefer; L Ma; S L Schrier
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

8.  The signaling pathways of erythropoietin and interferon-gamma differ in preventing the apoptosis of mature erythroid progenitor cells.

Authors:  Kittiphong Paiboonsukwong; Ilseung Choi; Takamitsu Matsushima; Yasunobu Abe; Junji Nishimura; Pranee Winichagoon; Suthat Fucharoen; Hajime Nawata; Koichiro Muta
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

9.  Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy.

Authors:  T Ikuta; Y W Kan; P S Swerdlow; D V Faller; S P Perrine
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

10.  Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

Authors:  A F Collins; H A Pearson; P Giardina; K T McDonagh; S W Brusilow; G J Dover
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

View more
  15 in total

1.  A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.

Authors:  Poramin Patthamalai; Suthat Fuchareon; Nattawara Chaneiam; Richard G Ghalie; David H K Chui; Michael S Boosalis; Susan P Perrine
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

2.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

3.  Extracts from Plastrum testudinis promote proliferation of rat bone-marrow-derived mesenchymal stem cells.

Authors:  D F Chen; H P Zeng; S H Du; H Li; J H Zhou; Y W Li; T T Wang; Z C Hua
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

4.  An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo.

Authors:  Douglas V Faller; Serguei A Castaneda; Daohong Zhou; Merriline Vedamony; Peter E Newburger; Gary L White; Stanley Kosanke; P Artur Plett; Christie M Orschell; Michael S Boosalis; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2016-10-31       Impact factor: 3.039

5.  Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.

Authors:  Michael S Boosalis; Serguei A Castaneda; Marie Trudel; Rodwell Mabaera; Gary L White; Christopher H Lowrey; David W Emery; Marthe-Sandrine Eiymo Mwa Mpollo; Ling Shen; William A Wargin; Regine Bohacek; Douglas V Faller; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2011-08-15       Impact factor: 3.039

6.  A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.

Authors:  Suthat Fucharoen; Adlette Inati; Noppadol Siritanaratku; Swee L Thein; William C Wargin; Suzanne Koussa; Ali Taher; Nattawara Chaneim; Michael Boosalis; Ronald Berenson; Susan P Perrine
Journal:  Br J Haematol       Date:  2013-03-27       Impact factor: 6.998

7.  Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Authors:  Robert A Parise; Jan H Beumer; Cyrous O Kangani; Julianne L Holleran; Julie L Eiseman; Nicola F Smith; Joseph M Covey; Susan P Perrine; Merrill J Egorin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-08       Impact factor: 3.205

8.  A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth Ataga; Marvin Reid; Elliott P Vichinsky; Lynne Neumayr; Loray Blair-Britt; Richard Labotka; Jonathan Glass; Jeffrey R Keefer; William A Wargin; Ronald Berenson; Susan P Perrine
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

9.  Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells.

Authors:  Himanshu Bhatia; Jennifer L Hallock; Amrita Dutta; Shay Karkashon; Lauren S Sterner; Toru Miyazaki; Ann Dean; Jane A Little
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

10.  Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives.

Authors:  Susan P Perrine; Rishikesh Mankidy; Michael S Boosalis; James J Bieker; Douglas V Faller
Journal:  Eur J Haematol       Date:  2009-02-05       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.